CSBio CSBio

X
[{"orgOrder":0,"company":"OncoArendi Therapeutics","sponsor":"Galapagos","pharmaFlowCategory":"D","amount":"$380.8 million","upfrontCash":"$29.7 million","newsHeadline":"OncoArendi and Galapagos Enter Into Exclusive Collaboration on Chitinase Inhibitors in Fibrosis","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"POLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"OncoArendi Therapeutics"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            OncoArendi Therapeutics gains global development and commercialization rights of OncoArendi’s OATD-01. OATD-01 is a Phase 2-ready chitotriosidase/acidic mammalian chitinase inhibitor to treat Idiopathic pulmonary fibrosis and other diseases with a fibrotic component.

            Lead Product(s): OATD-01

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: OATD-01

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Galapagos

            Deal Size: $380.8 million Upfront Cash: $29.7 million

            Deal Type: Licensing Agreement November 05, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY